NASDAQ: LFST - LifeStance Health Group, Inc.

Yield per half year: +27.32%
Sector: Healthcare

Company Analysis LifeStance Health Group, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (7.27 $) is less than fair price (8.24 $)
  • The stock's return over the last year (16.13%) is higher than the sector average (-33.16%).

Disadvantages

  • Dividends (0%) are below the sector average (0.5496%).
  • Current debt level 14.76% has increased over 5 years from 0%.
  • The company's current efficiency (ROE=-13.04%) is lower than the sector average (ROE=9.61%)

Similar companies

DENTSPLY SIRONA

Amgen

Alexion

ABIOMED

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

LifeStance Health Group, Inc. Healthcare Index
7 days 6.6% 1% 1.2%
90 days 26.4% -48.3% 7.8%
1 year 16.1% -33.2% 34.2%

LFST vs Sector: LifeStance Health Group, Inc. has outperformed the "Healthcare" sector by 49.29% over the past year.

LFST vs Market: LifeStance Health Group, Inc. has significantly underperformed the market by -18.07% over the past year.

Stable price: LFST is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: LFST with weekly volatility of 0.3103% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 2.73

3.2. Revenue

EPS -0.5069
ROE -13.04%
ROA -8.34%
ROIC -21.54%
Ebitda margin -10.13%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (7.27 $) is lower than the fair price (8.24 $).

Price not significantly lower than the fair price: The current price (7.27 $) is slightly lower than the fair price by 13.3%.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.12).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (2.01) is lower than that of the sector as a whole (4.82).

P/BV vs Market: The company's P/BV (2.01) is lower than that of the market as a whole (3.1).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (2.73) is lower than that of the sector as a whole (33.76).

P/S vs Market: The company's P/S indicator (2.73) is lower than that of the market as a whole (10.15).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-30.95) is lower than that of the sector as a whole (-22.12).

EV/Ebitda vs Market: The company's EV/Ebitda (-30.95) is lower than that of the market as a whole (18.05).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -640.87% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-640.87%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).

5.4. ROE

ROE vs Sector: The company's ROE (-13.04%) is lower than that of the sector as a whole (9.61%).

ROE vs Market: The company's ROE (-13.04%) is lower than that of the market as a whole (10.88%).

5.5. ROA

ROA vs Sector: The company's ROA (-8.34%) is lower than that of the sector as a whole (0.3359%).

ROA vs Market: The company's ROA (-8.34%) is lower than that of the market as a whole (6.5%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-21.54%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-21.54%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (14.76%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 0% to 14.76%.

Excess of debt: The debt is not covered by net income, percentage -177%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5496%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
13.11.2024 Miller Lisa K
Officer
Purchase 7.45 78 523 10 540
12.03.2024 Pantaleoni Pablo
Chief Digital Officer
Sale 6.76 292 735 43 304
03.01.2024 Cipollone Paula
See Remarks
Sale 7.45 25 099 3 369
08.09.2022 Gouk Warren
Chief Administrative Officer
Sale 9.01 465 565 51 672

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum LifeStance Health Group, Inc.

9.3. Comments